SCHEMBL1648249

SCHEMBL1648249

CCOC(=O)c1ccc(CSc2ccccc2C)c(Br)c1OC

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.42
LMNA P02545 4/20 0.42
TSHR P16473 3/20 0.42
RAB9A P51151 3/20 0.42
MAPK1 P28482 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
ALOX5 P09917 2/20 0.41
ALDH1A1 P00352 5/20 0.38
HPGD P15428 2/20 0.38
NPSR1 Q6W5P4 2/20 0.37
HSD17B10 Q99714 1/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
KDM4E B2RXH2 3/20 0.36
GAA P10253 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
NPC1 O15118 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6844873 0.82 ALOX5 (0.46) MAPTLMNATSHRRAB9AMAPK1
SCHEMBL18801058 0.80 ALOX5 (0.48) MAPTLMNATSHRRAB9AMAPK1
SCHEMBL1647829 0.74 TSHR (0.44) LMNATSHRRAB9AMAPK1SMN1; SMN2
SCHEMBL28104591 0.72 ALDH1A1 (0.51) MAPTLMNATSHRRAB9AMAPK1
SCHEMBL18801279 0.72 ALDH1A1 (0.44) MAPTLMNATSHRRAB9AMAPK1
SCHEMBL11678098 0.71 TSHR (0.63) MAPTLMNATSHRRAB9AMAPK1
SCHEMBL8493449 0.70 TSHR (0.42) MAPTLMNATSHRSMN1; SMN2ALDH1A1
SCHEMBL29196257 0.69 TSHR (0.59) MAPTLMNATSHRSMN1; SMN2ALDH1A1
SCHEMBL23773427 0.68 TSHR (0.68) MAPTLMNATSHRALDH1A1HPGD
SCHEMBL670404 0.68 TSHR (0.58) MAPTLMNATSHRALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2486004-B1 SULPHONE COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY ZAFGEN INC (US) 2017-05-03 EP disclosed
US-20160051531-A1 SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME ZAFGEN INC (US) 2016-02-25 US disclosed
US-9067905-B2 Sulphone compounds and methods of making and using same ZAFGEN, INC. (US) 2015-06-30 US disclosed
US-20130053364-A1 Sulphone Compounds and Methods of Making and Using Same ZAFGEN, INC. 2013-02-28 US disclosed
EP-2486004-A2 SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME Zafgen Corporation (US) 2012-08-15 EP disclosed
WO-2011044506-A2 SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME ZAFGEN CORPORATION (US) 2011-04-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160051531-A1 SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME METAP2, DNPEP, STS MAPT 3145/4885LMNA 4621/4885TSHR 3569/4885
US-20130053364-A1 Sulphone Compounds and Methods of Making and Using Same METAP2, DNPEP, STS MAPT 3145/4885LMNA 4621/4885TSHR 3569/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.